Vizgen Charts Path to 3D Biology and Advanced Organoid Analysis

WALTHAM, Mass. – February 19, 2026

Vizgen, a key player in the high-resolution spatial biology market, is poised to detail an ambitious technology roadmap at the upcoming Advances in Genome Biology and Technology (AGBT) General Meeting in Orlando. The company plans to showcase a suite of innovations targeting three critical areas: advanced analysis of organoids, significant upgrades to its flagship MERSCOPE platform, and a bold leap into the complexities of thick tissue imaging, or "3D" spatial biology. This strategic push aims to accelerate drug discovery and deepen the fundamental understanding of disease by providing researchers with more powerful and biologically relevant tools.

Aligning with the Future of Human-Relevant Research

A central pillar of Vizgen's new strategy is its focus on the spatially-resolved molecular profiling of organoids. This move strategically aligns the company with a major regulatory and scientific shift toward New Approach Methodologies (NAMs). These lab-grown, 3D organ-mimicking structures are increasingly championed by agencies like the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) as more predictive and ethical alternatives to traditional animal testing.

This industry-wide transition was significantly accelerated by the FDA Modernization Act 2.0, signed into law in late 2022, which removed the mandate for animal testing in preclinical drug development. The FDA has since followed up with plans to phase out such requirements for certain drug classes, explicitly encouraging the use of organoids and other human-relevant models. Vizgen’s focus on providing high-resolution spatial data from these models directly addresses the growing need for robust validation tools in this new regulatory landscape.

“At Vizgen, we are working to develop new capabilities for researchers who are currently working with or want to work with organoids, especially for earlier, more predictive drug evaluation,” said Jiang He, VP & Portfolio Owner, Reagents & Sci. Affairs, at Vizgen. “As the industry shifts toward more human-relevant and translational model systems, we’re preparing for the era to come through collaborative R&D work with the global scientific community and partners.”

Enhancing the Toolbox in a Crowded Spatial Race

To empower this new wave of research, Vizgen announced significant planned enhancements for its MERSCOPE Ultra platform throughout 2026. A key feature is the expansion of its predesigned panels and the introduction of "MERSCOPE Add-On Genes," a modular customization capability. This allows researchers to seamlessly add new targets to validated experiments without starting from scratch, promising to accelerate hypothesis-driven research.

The company is also targeting workflow efficiency, revealing plans for new MERSCOPE slides with optimized chemistry and a streamlined pre-analytical process that unlocks high-flexibility protein co-detection alongside RNA. This focus on multi-omic capability—simultaneously measuring multiple types of molecules—is critical in a market where researchers demand increasingly comprehensive data from precious samples.

These hardware and chemistry updates are matched by a push into scalable data analysis, with the upcoming launch of a cloud-based platform for MERFISH 2.0™ data and advanced AI-driven segmentation algorithms. This move is essential for Vizgen to keep pace with competitors like 10x Genomics, NanoString, and Illumina, all of whom are investing heavily in cloud-based ecosystems to manage the massive datasets generated by spatial technologies.

The Next Frontier: Charting the Course for 3D Spatial Biology

Perhaps the most forward-looking part of Vizgen's roadmap is its progress toward true three-dimensional spatial biology. For years, spatial analysis has been largely confined to thin, 2D tissue slices, which can miss crucial information about long-range cellular interactions, complex tissue architecture, and the full context of the tumor microenvironment. Vizgen’s work on thick tissue imaging aims to break through this limitation.

The demand for 3D analysis is palpable across the research community, as it promises to unlock a more holistic understanding of how tissues are organized and how that organization breaks down in disease. However, the technical hurdles—from reagent penetration and imaging depth to processing terabytes of data—are substantial.

Vizgen is not alone in this pursuit. The AGBT conference itself will underscore the competitive urgency, with rival Stellaromics launching its Pyxa™ platform, which is being marketed as the first commercially available system for multiplexed 3D spatial transcriptomics. This burgeoning competition highlights the industry's collective recognition that 3D is the next major frontier in understanding biology in situ.

A Unified Vision for Mapping Disease

Taken together, Vizgen's planned innovations represent a cohesive strategy to build a more complete and biologically accurate map of human health and disease. By enabling deep profiling of human-relevant organoids, providing more flexible and powerful platform tools, and pushing the boundaries into the third dimension, the company is aiming to equip researchers to ask and answer more complex questions.

This comprehensive approach was summarized by Vizgen's CEO, Rob Carson. “Vizgen is advancing a bold roadmap to unlock deeper biological insight through spatial multi-omics,” he stated. “Our pipeline is consistent with our purpose: a map for every disease, a path for every cure.”

As researchers gather in Orlando, the presentation of this roadmap will be closely watched. It not only signals Vizgen's direction but also reflects the broader ambitions of the entire spatial biology field to move from generating beautiful images to providing actionable insights that can transform drug development and, ultimately, patient care. The detailed poster on "High-Resolution Profiling of Neuronal Transcription Factors" will offer an early glimpse into the practical power of these new capabilities.